Optimales Timing der Tiefen Hirnstimulation bei M. Parkinson

S. J. Groiss; A. Schnitzler

doi:10.1055/s-0034-1395638

Aktuelle Neurologie, Inhaltsverzeichnis

Aktuelle Neurologie 2014; 41(10): 579-585
DOI: 10.1055/s-0034-1395638

Übersicht

Optimales Timing der Tiefen Hirnstimulation bei M. Parkinson

Optimal Timing of Deep Brain Stimulation for Parkinsonʼs Disease

S. J. Groiss

¹Institut für klinische Neurowissenschaften und Medizinische Psychologie & Neurologische Klinik – Zentrum für Bewegungsstörungen und Neuromodulation, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf

,

A. Schnitzler

¹Institut für klinische Neurowissenschaften und Medizinische Psychologie & Neurologische Klinik – Zentrum für Bewegungsstörungen und Neuromodulation, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf

› Institutsangaben

Abstract

Zusammenfassung

Die Tiefe Hirnstimulation (THS) gilt als bedeutendste Entwicklung in der Behandlung des idiopathischen Parkinson-Syndroms (IPS) seit der Einführung von Levodopa. Bisher wurde die THS beim IPS allerdings erst im weit fortgeschrittenen Krankheitsstadium als Ultima Ratio zur Behandlung medikamentös austherapierter, schwerer motorischer Fluktuationen und Dyskinesien oder medikamentenrefraktärer Tremores eingesetzt. Oft hat die Erkrankung jedoch bereits in mittleren Krankheitsstadien erhebliche psychosoziale Auswirkungen und führt z. B. durch Berufsunfähigkeit oder soziale Isolation zu einer deutlichen Einschränkung der Lebensqualität. Neuere Studienergebnisse zeigen, dass eine THS des Nucleus subthalamicus (STN) im Vergleich zur medikamentösen Therapie die Lebensqualität auch bei Patienten mit motorischen Komplikationen in früheren Stadien signifikant und relevant verbessern kann. Zur möglichst langfristigen Erhaltung der Lebensqualität ist deshalb die STN-THS bereits in früheren Krankheitsstadien nach dem Auftreten von motorischen Komplikationen als Therapieoption in Betracht zu ziehen.

Abstract

Deep brain stimulation (DBS) is considered the most important development in the treatment of Parkinsonʼs disease (PD) since the introduction of levodopa. So far, DBS has been used as ultima ratio for the treatment of severe motor fluctuations and dyskinesias or refractory tremor in advanced PD. However, the disease frequently leads to considerable psychosocial consequences such as occupational disability or social isolation with consecutive impairment in quality of life already at earlier disease stages. Recent research has shown DBS of the subthalamic nucleus (STN) to be superior to best medical treatment in improving quality of life and motor symptoms in PD patient with motor complication at an earlier disease stage. STN-DBS should be considered as treatment option earlier in the disease course after the occurrence of motor fluctuations preferably for long term maintenance of quality of life.

Schlüsselwörter

Tiefe Hirnstimulation - EARLYSTIM - Morbus Parkinson

Keywords

Deep brain stimulation - EARLYSTIM - Parkinsonʼs disease

Volltext

Referenzen

Literatur
1 Benabid AL, Pollak P, Louveau A et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Applied Neurophysiology 1987; 50: 344-346
2 Deuschl G, Paschen S, Witt K. Clinical outcome of deep brain stimulation for Parkinson’s disease. Handbook of Clinical Neurology 2013; 116: 107-128
3 Esselink RAJ, De Bie RMA, De Haan RJ et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004; 62: 201-207
4 Schuurman PR, Bosch DA, Bossuyt PM et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. New Engl J Med 2000; 342: 461-468
5 Groiss SJ, Wojtecki L, Südmeyer M et al. Deep brain stimulation in Parkinson’s disease. Ther Adv Neurol Disord 2009; 2: 20-28
6 Kleiner-Fisman G, Herzog J, Fisman DN et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006; 21 (Suppl. 01) S290-S304
7 Welter ML, Houeto JL, Tezenas du Montcel S et al. Clinical predictive factors of subthalamic stimulation in Parkinson’s disease. Brain 2002; 125: 575-583
8 Charles PD, Van Blercom N, Krack P et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002; 59: 932-934
9 Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. New Engl J Med 2006; 355: 896-908
10 Weaver FM, Follett K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301: 63-73
11 Follett Ka, Weaver FM, Stern M et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. New Engl J Med 2010; 362: 2077-2091
12 Schuepbach WMM, Rau J, Knudsen K et al. Neurostimulation for Parkinson’s disease with early motor complications. New Engl J Med 2013; 368: 610-622
13 Volkmann J, Ceballos-Baumann A. Wann ist der richtige Zeitpunkt für eine tiefe Hirnstimulation bei Morbus Parkinson?. Akt Neurol 2009; 36: S7-S11
14 Okun MS, Foote KD. Parkinson’s disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Review of Neurotherapeutics 2010; 10: 1847-1857
15 Fasano A, Romito LM, Daniele A et al. Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 2010; 133: 2664-2676
16 Zibetti M, Merola A, Rizzi L et al. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson’s disease. Mov Disord 2011; 26: 2327-2334
17 Castrioto A, Lozano AM, Poon Y-Y et al. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011; 68: 1550-1556
18 Volkmann J. Update on surgery for Parkinson’s disease. Curr Opin Neurol 2007; 20: 465-469
19 Odekerken VJJ, Van Laar T, Staal MJ et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet Neurology 2013; 12: 37-44
20 Okun MS, Gallo BV, Mandybur G et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson’s disease: an open-label randomised controlled trial. Lancet Neurology 2012; 11: 140-149
21 Deep-Brain Stimulation for Parkinson’s Disease Study Group . Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 2001; 345: 956-963
22 Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. New Engl J Med 2003; 349: 1925-1934
23 Volkmann J, Allert N, Voges J et al. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Ann Neurol 2004; 55: 871-875
24 Moro E, Lozano AM, Pollak P et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord 2010; 25: 578-586
25 Deuschl G, Agid Y. Subthalamic neurostimulation for Parkinson’s disease with early fluctuations: balancing the risks and benefits. Lancet Neurology 2013; 12: 1025-1034
26 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442
27 Kimmelman J, Duckworth K, Ramsay T et al. Risk of surgical delivery to deep nuclei: a meta-analysis. Mov Disord 2011; 26: 1415-1421
28 Zrinzo L, Foltynie T, Limousin P et al. Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. Journal of Neurosurgery 2012; 116: 84-94
29 Voges J, Hilker R, Bötzel K et al. Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 2007; 22: 1486-1489
30 Seijo F, Alvarez de Eulate Beramendi S, Santamarta Liébana E et al. Surgical adverse events of deep brain stimulation in the subthalamic nucleus of patients with Parkinson’s disease. The learning curve and the pitfalls. Acta Neurochirurgica. 2014 156. 1505-1512
31 Hamani C, Richter E, Schwalb JM et al. Bilateral subthalamic nucleus stimulation for Parkinson’s disease: a systematic review of the clinical literature. Neurosurgery 2005; 56: 1313-1321 discussion 1321–1324
32 Hamani C, Lozano AM. Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg 2006; 84: 248-251
33 Videnovic A, Metman LV. Deep brain stimulation for Parkinson’s disease: prevalence of adverse events and need for standardized reporting. Mov Disord 2008; 23: 343-349
34 Witt K, Granert O, Daniels C et al. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson’s disease: results from a randomized trial. Brain 2013; 136: 2109-2119
35 Lyons KE, Wilkinson SB, Overman J et al. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 2004; 63: 612-616
36 Oh MY, Abosch A, Kim SH et al. Long-term hardware-related complications of deep brain stimulation. Neurosurgery. 2002; 50: 1268-1274 discussion 1274–1276
37 Falowski S, Ooi YC, Smith A et al. An evaluation of hardware and surgical complications with deep brain stimulation based on diagnosis and lead location. Stereotact Funct Neurosurg 2012; 90: 173-180
38 Guridi J, Rodriguez-Oroz MC, Alegre M et al. Hardware complications in deep brain stimulation: electrode impedance and loss of clinical benefit. Parkinsonism Relat Disord 2012; 18: 765-769
39 Vesper J, Slotty PJ. Technische Innovationen in der tiefen Hirnstimulation. Nervenarzt 2014; 85: 169-175
40 Guehl D, Cuny E, Benazzouz A et al. Side-effects of subthalamic stimulation in Parkinson’s disease: clinical evolution and predictive factors. Eur J Neurol 2006; 13: 963-971
41 Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson’s disease. Mov Disord 2006; 21 (Suppl. 01) S284-S289
42 Krack P, Fraix V, Mendes A et al. Postoperative management of subthalamic nucleus stimulation for Parkinson’s disease. Mov Disord 2002; 17 (Suppl. 03) S188-S197
43 Macia F, Perlemoine C, Coman I et al. Parkinson’s disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 2004; 19: 206-212
44 Bannier S, Montaurier C, Derost PP et al. Overweight after deep brain stimulation of the subthalamic nucleus in Parkinson disease: long term follow-up. J Neurol Neurosurg Psychiatry 2009; 80: 484-488
45 Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurology 2009; 8: 464-474
46 Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nature Reviews Neurology 2010; 6: 487-498
47 Funkiewiez A, Ardouin C, Caputo E et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 834-839
48 Thobois S, Ardouin C, Lhommée E et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111-1127
49 Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurology 2008; 7: 605-614
50 Smeding HMM, Speelman JD, Koning-Haanstra M et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006; 66: 1830-1836
51 Wojtecki L, Timmermann L, Jörgens S et al. Frequency-dependent reciprocal modulation of verbal fluency and motor functions in subthalamic deep brain stimulation. Arch Neurol 2006; 63: 1273-1276
52 Parsons TD, Rogers SA, Braaten AJ et al. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a meta-analysis. Lancet Neurology 2006; 5: 578-588
53 Okun MS, Fernandez HH, Wu SS et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009; 65: 586-595
54 Wojtecki L, Nickel J, Timmermann L et al. Pathological crying induced by deep brain stimulation. Mov Disord 2007; 22: 1314-1316
55 Okun MS, Green J, Saben R et al. Mood changes with deep brain stimulation of STN and GPi: results of a pilot study. J Neurol Neurosurg Psychiatry 2003; 74: 1584-1586
56 Krack P, Kumar R, Ardouin C et al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 2001; 16: 867-875
57 Weintraub D, Duda JE, Carlson K et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson’s disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2013; 84: 1113-1118
58 Agid Y, Schüpbach M, Gargiulo M et al. Neurosurgery in Parkinson’s disease: the doctor is happy, the patient less so?. J Neural Transm Suppl 2006; 70: 409-414
59 Schüpbach M, Gargiulo M, Welter ML et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body?. Neurology 2006; 66: 1811-1816
60 Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet 1987; 1: 871
61 Dewey RB, Hutton JT, LeWitt PA et al. Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385-1392
62 Olanow CW, Kieburtz K, Odin P et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology 2014; 13: 141-149
63 Elias WJ, Huss D, Voss T et al. A pilot study of focused ultrasound thalamotomy for essential tremor. New Engl J Med 2013; 369: 640-648
64 Schrag A, Banks P. Time of loss of employment in Parkinson’s disease. Mov Disord 2006; 21: 1839-1843
65 Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci 2006; 248: 151-157
66 Russmann H, Ghika J, Villemure J-G et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004; 63: 1952-1954
67 Shalash A, Alexoudi A, Knudsen K et al. The impact of age and disease duration on the long term outcome of neurostimulation of the subthalamic nucleus. Parkinsonism Relat Disord 2014; 20: 47-52
68 Kempster PA, Williams DR, Selikhova M et al. Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 2007; 130: 2123-2128
69 Saint-Cyr JA, Trépanier LL, Kumar R et al. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson’s disease. Brain 2000; 123: 2091-2108
70 Derost P-P, Ouchchane L, Morand D et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?. Neurology 2007; 68: 1345-1355
71 Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M et al. Does ageing influence deep brain stimulation outcomes in Parkinson’s disease?. Mov Disord 2007; 22: 1457-1463
72 Eggington S, Valldeoriola F, Chaudhuri KR et al. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease. J Neurol 2014; 261: 106-116
73 Zahodne LB, Okun MS, Foote KD et al. Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. J Neurol 2009; 256: 1321-1329
74 Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-1436
75 Wichmann T, DeLong MR, Guridi J et al. Milestones in research on the pathophysiology of Parkinson’s disease. Mov Disord 2011; 26: 1032-1041
76 Maesawa S, Kaneoke Y, Kajita Y et al. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg 2004; 100: 679-687
77 Harnack D, Meissner W, Jira JA et al. Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. Exp Neurol 2008; 210: 257-260
78 Wallace VCJ, Blackbeard J, Segerdahl AR et al. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain 2007; 130: 2688-2702
79 Hilker R, Portman AT, Voges J et al. Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005; 76: 1217-1221
80 Toft M, Lilleeng B, Ramm-Pettersen J et al. Long-term efficacy and mortality in Parkinson’s disease patients treated with subthalamic stimulation. Mov Disord 2011; 26: 1931-1934